[{"id":"b57cb3c0-4fb2-4fdc-add3-151c7aaf3f51","acronym":"SAINT","url":"https://clinicaltrials.gov/study/NCT03138161","created_at":"2024-04-18T20:51:31.500Z","updated_at":"2025-02-25T12:26:41.043Z","phase":"Phase 1/2","brief_title":"SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma","source_id_and_acronym":"NCT03138161 - SAINT","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 07/31/2031","study_completion_date":" 07/31/2031","last_update_posted":"2025-02-24"},{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"548aa500-8c12-4f07-a648-778d8d4336f5","acronym":"TOMAS2","url":"https://clinicaltrials.gov/study/NCT03838744","created_at":"2021-01-18T18:56:57.653Z","updated_at":"2025-02-25T15:08:19.930Z","phase":"Phase 2","brief_title":"Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.","source_id_and_acronym":"NCT03838744 - TOMAS2","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 130","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-12-04"},{"id":"939d1cf5-27ac-48f1-9f3d-96f6a19b535a","acronym":"NRG-HN008","url":"https://clinicaltrials.gov/study/NCT04533750","created_at":"2021-01-29T07:21:21.551Z","updated_at":"2024-07-02T16:34:37.751Z","phase":"Phase 1","brief_title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","source_id_and_acronym":"NCT04533750 - NRG-HN008","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" CDKN2A negative","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/20/2021","start_date":" 12/20/2021","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-06"},{"id":"9a8bbdf2-e4b9-4ba0-a574-823381bdf9e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05610891","created_at":"2022-11-09T13:56:43.468Z","updated_at":"2024-07-02T16:35:03.279Z","phase":"Phase 1","brief_title":"Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG","source_id_and_acronym":"NCT05610891","lead_sponsor":"Cellectar Biosciences, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e iopofosine I-131 (CLR 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-05-16"},{"id":"12ef23c8-0f04-4348-90aa-89217bc8e0c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04555577","created_at":"2021-07-05T17:32:33.242Z","updated_at":"2024-07-02T16:35:03.500Z","phase":"Phase 1","brief_title":"Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma","source_id_and_acronym":"NCT04555577","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 09/20/2020","start_date":" 09/20/2020","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-05-15"},{"id":"abd76cdb-12d9-4904-9a08-3b3400169164","acronym":"","url":"https://clinicaltrials.gov/study/NCT02993146","created_at":"2021-01-29T07:13:49.401Z","updated_at":"2024-07-02T16:35:11.807Z","phase":"Phase 1","brief_title":"Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases","source_id_and_acronym":"NCT02993146","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ropidoxuridine (IPdR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 08/19/2022","primary_completion_date":" 08/19/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-04-02"},{"id":"6546b0c5-710f-4af5-b959-a7792033251c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02381561","created_at":"2021-01-29T07:07:48.027Z","updated_at":"2024-07-02T16:35:15.997Z","phase":"Phase 1","brief_title":"Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy","source_id_and_acronym":"NCT02381561","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ropidoxuridine (IPdR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 11/08/2018","primary_completion_date":" 11/08/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-03-07"},{"id":"979632e5-5844-47cd-bb14-5dedd6d753fe","acronym":"TRABTRAP","url":"https://clinicaltrials.gov/study/NCT05597917","created_at":"2022-10-28T13:57:00.387Z","updated_at":"2024-07-02T16:35:25.392Z","phase":"Phase 3","brief_title":"tTF-NGR Randomized Study - STS","source_id_and_acronym":"NCT05597917 - TRABTRAP","lead_sponsor":"Universität Münster","biomarkers":" BCOR • ANPEP","pipe":"","alterations":" ","tags":["BCOR • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-12-22"},{"id":"73b9aa98-7882-4ef9-8648-1da0dc4ba8a9","acronym":"SARC037","url":"https://clinicaltrials.gov/study/NCT04067115","created_at":"2021-01-18T19:55:32.138Z","updated_at":"2024-07-02T16:35:25.576Z","phase":"Phase 1/2","brief_title":"SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients","source_id_and_acronym":"NCT04067115 - SARC037","lead_sponsor":"Sarcoma Alliance for Research through Collaboration","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Yondelis (trabectedin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/05/2021","start_date":" 01/05/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-12-21"},{"id":"f7315e28-fa58-4818-96a0-d6747f9a7418","acronym":"ISG-MCS","url":"https://clinicaltrials.gov/study/NCT04305548","created_at":"2022-03-10T21:59:21.461Z","updated_at":"2024-07-02T16:35:37.152Z","phase":"Phase 2","brief_title":"Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma","source_id_and_acronym":"NCT04305548 - ISG-MCS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" HEY1 • NCOA2","pipe":"","alterations":" ","tags":["HEY1 • NCOA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-09-13"},{"id":"aceff7a2-5092-43b8-8aad-dcf758269bb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005847","created_at":"2021-01-17T23:51:33.434Z","updated_at":"2024-07-02T16:35:45.079Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","source_id_and_acronym":"NCT00005847","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • vinorelbine tartrate • mitoxantrone • Emcyt (estramustine)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 04/05/2001","start_date":" 04/05/2001","primary_txt":" Primary completion: 07/01/2004","primary_completion_date":" 07/01/2004","study_txt":"","study_completion_date":"","last_update_posted":"2023-06-22"},{"id":"985dbe59-edc4-40c6-b4c4-daf7da0b5372","acronym":"TRASTS","url":"https://clinicaltrials.gov/study/NCT02275286","created_at":"2022-06-01T12:55:54.963Z","updated_at":"2024-07-02T16:35:46.759Z","phase":"Phase 1/2","brief_title":"Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients","source_id_and_acronym":"NCT02275286 - TRASTS","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" FAS","pipe":"","alterations":" ","tags":["FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2023-05-31"},{"id":"ac955a6c-ca84-4da0-949d-41199f5759b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03478462","created_at":"2021-01-18T17:08:27.106Z","updated_at":"2024-07-02T16:35:47.764Z","phase":"Phase 1","brief_title":"Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma","source_id_and_acronym":"NCT03478462","lead_sponsor":"Cellectar Biosciences, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e iopofosine I-131 (CLR 131)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 09/25/2022","primary_completion_date":" 09/25/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-05-17"},{"id":"8eae4547-c419-42bc-bcef-a0c556fe5a48","acronym":"REVOCAN","url":"https://clinicaltrials.gov/study/NCT04826198","created_at":"2021-04-01T16:52:33.019Z","updated_at":"2024-07-02T16:35:51.390Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months","source_id_and_acronym":"NCT04826198 - REVOCAN","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" BRCA • MUC16","pipe":"","alterations":" ","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Zejula (niraparib) • Rubraca (rucaparib) • AsiDNA (etidaligide)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-04-05"},{"id":"a95aec49-3776-4a7a-a329-90349bf3ac75","acronym":"TRAMUNE","url":"https://clinicaltrials.gov/study/NCT03085225","created_at":"2021-01-18T15:11:58.019Z","updated_at":"2025-02-25T14:57:54.358Z","phase":"Phase 1","brief_title":"Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.","source_id_and_acronym":"NCT03085225 - TRAMUNE","lead_sponsor":"Institut Bergonié","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2023-03-03"},{"id":"34fb42bf-5489-4d14-b865-5d4cdb3a0b49","acronym":"NiTraSarc","url":"https://clinicaltrials.gov/study/NCT03590210","created_at":"2021-01-18T17:39:22.163Z","updated_at":"2025-02-25T14:27:17.508Z","phase":"Phase 2","brief_title":"Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas","source_id_and_acronym":"NCT03590210 - NiTraSarc","lead_sponsor":"University Medicine Greifswald","biomarkers":" PD-L1 • CTLA4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 02/12/2022","primary_completion_date":" 02/12/2022","study_txt":" Completion: 02/12/2022","study_completion_date":" 02/12/2022","last_update_posted":"2022-11-08"},{"id":"79ba1568-d944-4f02-8f3a-52d7c5e73775","acronym":"TvsCH","url":"https://clinicaltrials.gov/study/NCT05512676","created_at":"2022-08-23T14:55:39.488Z","updated_at":"2024-07-02T16:36:05.041Z","phase":"","brief_title":"Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum","source_id_and_acronym":"NCT05512676 - TvsCH","lead_sponsor":"Oslo University Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pegylated liposomal doxorubicin • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 03/07/2016","start_date":" 03/07/2016","primary_txt":" Primary completion: 05/20/2019","primary_completion_date":" 05/20/2019","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2022-08-23"},{"id":"ae77e194-ff53-4dfc-845b-4d87595d81c6","acronym":"NIMES-ROC","url":"https://clinicaltrials.gov/study/NCT02825420","created_at":"2021-10-29T19:53:55.831Z","updated_at":"2024-07-02T16:36:22.169Z","phase":"","brief_title":"Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients","source_id_and_acronym":"NCT02825420 - NIMES-ROC","lead_sponsor":"PharmaMar","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 220","initiation":"Initiation: 07/28/2015","start_date":" 07/28/2015","primary_txt":" Primary completion: 09/18/2019","primary_completion_date":" 09/18/2019","study_txt":" Completion: 09/18/2019","study_completion_date":" 09/18/2019","last_update_posted":"2021-10-29"},{"id":"5b155166-456e-4e98-ab35-93aa83881242","acronym":"Mito23","url":"https://clinicaltrials.gov/study/NCT02903004","created_at":"2021-01-18T14:14:50.207Z","updated_at":"2024-07-02T16:36:25.860Z","phase":"Phase 3","brief_title":"Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients","source_id_and_acronym":"NCT02903004 - Mito23","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Yondelis (trabectedin) • topotecan • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 242","initiation":"Initiation: 04/11/2016","start_date":" 04/11/2016","primary_txt":" Primary completion: 12/20/2018","primary_completion_date":" 12/20/2018","study_txt":" Completion: 12/20/2018","study_completion_date":" 12/20/2018","last_update_posted":"2021-08-25"},{"id":"419a98b5-d2bf-415b-9307-4fc2b382b434","acronym":"TOMAS","url":"https://clinicaltrials.gov/study/NCT02398058","created_at":"2021-04-14T18:53:45.928Z","updated_at":"2025-02-25T15:06:31.322Z","phase":"Phase 1","brief_title":"Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)","source_id_and_acronym":"NCT02398058 - TOMAS","lead_sponsor":"Italian Sarcoma Group","biomarkers":" BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1","pipe":"","alterations":" ","tags":["BRCA1 • ERCC1 • ERCC2 • PARP1 • TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Yondelis (trabectedin)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/20/2014","start_date":" 07/20/2014","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2021-04-14"},{"id":"06f21240-c20d-439e-8665-60546964dae6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02866955","created_at":"2021-01-18T14:04:25.677Z","updated_at":"2024-07-02T16:36:49.051Z","phase":"Phase 2","brief_title":"Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.","source_id_and_acronym":"NCT02866955","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Emcyt (estramustine)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 06/15/2011","start_date":" 06/15/2011","primary_txt":" Primary completion: 08/08/2014","primary_completion_date":" 08/08/2014","study_txt":" Completion: 08/28/2015","study_completion_date":" 08/28/2015","last_update_posted":"2020-03-09"},{"id":"10270926-5ac6-4697-bea9-2ffc0991ea57","acronym":"ATREUS","url":"https://clinicaltrials.gov/study/NCT02194231","created_at":"2021-01-18T10:14:55.957Z","updated_at":"2024-07-02T16:36:50.984Z","phase":"Phase 2","brief_title":"ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)","source_id_and_acronym":"NCT02194231 - ATREUS","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HMGB1","pipe":"","alterations":" ","tags":["HMGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yondelis (trabectedin) • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 12/12/2019","primary_completion_date":" 12/12/2019","study_txt":" Completion: 12/12/2019","study_completion_date":" 12/12/2019","last_update_posted":"2020-01-23"},{"id":"6ffd26d0-764c-4b8b-a3bb-a291e30726d2","acronym":"ZENITH","url":"https://clinicaltrials.gov/study/NCT03159845","created_at":"2021-01-18T15:34:43.301Z","updated_at":"2024-07-02T16:36:51.816Z","phase":"Phase 2","brief_title":"Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies","source_id_and_acronym":"NCT03159845 - ZENITH","lead_sponsor":"Azienda Ospedaliero, Universitaria Pisana","biomarkers":" CD8 • CD28 • CD27","pipe":"","alterations":" ","tags":["CD8 • CD28 • CD27"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 09/10/2019","primary_completion_date":" 09/10/2019","study_txt":" Completion: 09/10/2019","study_completion_date":" 09/10/2019","last_update_posted":"2020-01-07"}]